Association between Systemic Lupus Erythematosus and Coronary Heart Disease: a retrospective case-control analysis and Mendelian Randomization Study - Chen, Jinyun; Tian, Junmei; Wang, Wen; Zhou, Shiliang; Zhang, Lu; Jiang, Wanlan; Cai, Mingyuan; Zhang, Peirong; Xu, Ting; Wu, Min (medRxiv, 2021)
Objectives To appraise the causal effect of systemic lupus erythematosus (SLE) for risk of Coronary heart disease (CHD).Methods We selected single nucleotide polymorphisms (SNPs) associated with SLE as instrumental variables (IVs) from three independent genome-wide association studies (GWAS), the three largest to date for SLE of European ancestry. Then we conducted two-sample Mendelian randomization (2SMR) analyses to estimate the effects of IVs on the odds of CHD and traditional coronary risk factors (including high LDL cholesterol levels, low HDL cholesterol levels, Apolipoprotein A-I, Apolipoprotein B, diabetes mellitus, and hypertension). Additionally, we searched for common risk loci between SLE and premature coronary atherosclerosis. Furthermore, we retrospectively reviewed the lipid profile of treatment-naïve SLE patients and age-matched healthy controls.Results Genetically predicted SLE did not increase the odds of CHD. Nevertheless, we found mild causal relationships between SLE and decreased HDL cholesterol levels, and between SLE and decreased apolipoprotein A-I. There was one common risk locus (rs597808) between SLE and premature coronary atherosclerosis at a genome-wide significance level (P<5 exttimes 10-8). Retrospective analysis showed decreased HDL-cholesterol (0.98 extpm0.516mmol/L vs. 1.46 extpm0.307mmol/L in female, 0.76 extpm0.199mmol/L vs. 1.19 extpm0.257mmol/L in male; both P<0.001) and apolipoprotein A-I (1.06 extpm0.314g/L vs. 1.37 extpm0.205g/L in female, 0.87 extpm0.174g/L vs. 1.24 extpm0.200g/L in male; both P<0.001) in naïve SLE patients.Conclusion SLE may accelerate coronary atherosclerosis in young patients by reducing HDL cholesterol and apolipoprotein A-I intrinsically, but it seems not to play a predominant role in CHD development in old patients.Competing Interest StatementThe authors have declared no competing interest.Funding Statementgrants from the Science and Technology Project of Changzhou Health Committee for Young Talents (QN201805)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of Soochow University and individual consent for this retrospective analysis was waived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article are available in the NHGRI-EBI GWAS catalog, at https://www.ebi.ac.uk/gwas/, and MR Base database, at http://app.mrbase.org. The cumulative risk curves of the risk loci for coronary artery atherosclerosis are available at ftp://share.sph.umich.edu/UKBB_SPACox_HRC/Survplot.